BCRX FY 2025 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$875M+94.1% YoY

Gross Profit

$856M97.8% margin

Operating Income

$341M39.0% margin

Net Income

$264M30.2% margin

EPS (Diluted)

$1.21

Cash Flow

Operating Cash Flow

$330M

Free Cash Flow

$327M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$514M

Total Liabilities

$633M

Stockholders' Equity

-$119M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$875M	$451M	+94.1%
Gross Profit	$856M	$438M	+95.3%
Operating Income	$341M	-$3M	+13508.9%
Net Income	$264M	-$89M	+396.9%